NKTR FINAL DEADLINE: Rosen Law Firm Reminds Nektar

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
141
NKTR FINAL DEADLINE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important December 31 Deadline in Class Action – NKTR

NEW YORK, Dec. 29, 2018 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from November 11, 2017 through October 2, 2018, inclusive (the “Class Period”) of the important December 31, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Nektar investors under the federal securities laws.

To join the Nektar class action, go to https://www.rosenlegal.com/cases-1440.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or zhalper@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) NKTR-214’s extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 31, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-1440.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or zhalper@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

-------------------------------

Contact Information:       Laurence Rosen, Esq.       Phillip Kim, Esq.       Zachary Halper, Esq.       The Rosen Law Firm, P.A.       275 Madison Avenue, 34 th Floor       New York, NY  10016       Tel: (212) 686-1060       Toll Free: (866) 767-3653       Fax: (212) 202-3827       lrosen@rosenlegal.com       pkim@rosenlegal.com       zhalper@rosenlegal.com       www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohat University Teams Up with MindHYVE.ai for AI Learning

Updated Category News Views 283

Kohat University Partners with MindHYVE.ai to Innovate Education In a significant advancement for higher education in the region, Kohat University of Science & Technology (KUST) has established a strategic partnership with MindHYVE.ai™. This collaboration aims to introduce ArthurAI™, an advanced learning platform that utilizes agentic AI technology, into its academic...

Continue Reading
Lulus Enhances Market Reach Through Innovative Collaborations

Updated Category News Views 336

Expanding Market Reach Through Strategic Collaborations LOS ANGELES, A prominent player in the fashion industry, Lulus is taking significant steps to enhance its market presence and reach customers in new and exciting ways. By initiating collaborations with various platforms, Lulus is keen on tapping into emerging retail channels and broadening its accessibility....

Continue Reading
Explore Top Gardening Trends for Fall by Calloway's Nursery

Updated Category News Views 172

Embracing Fall Gardening Trends with Calloway's Nursery As the seasons change, so does the opportunity to refresh our gardens and outdoor spaces. Calloway's Nursery is here to help you embrace the beauty of fall gardening. The nursery’s offerings are tailored to inspire Texans to create vibrant and inviting spaces. Fantastic Fall Container Gardens Container gardens are...

Continue Reading
happyactually Strengthens Leadership with Dr. Andia Shahzadi

Updated Category News Views 119

happyactually Appoints Dr. Andia Shahzadi as Chief Medical Officer happyactually, an innovative wellbeing technology firm, proudly announces the elevation of Dr. Andia Shahzadi to the position of Chief Medical Officer and Founding Member of the team. This change marks a significant step in the company's aim to empower life-conscious individuals through scientifically...

Continue Reading
Surrozen to Showcase Innovations at Investor Conference Soon

Updated Category News Views 76

Surrozen Announces Presentation at Healthcare Investor Conference Recently, Surrozen, Inc. (Nasdaq: SRZN), a pioneering biotechnology company based in South San Francisco, revealed that its management team will be presenting at an upcoming healthcare investor conference. The company specializes in targeted therapeutics that focus on selectively modulating the Wnt pathway,...

Continue Reading